| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/27/2001 | US20010025108 Thrombosis diseases |
| 09/27/2001 | US20010025051 Administering to a breast cancer patient an effective amount of hydroxy containing bicyclic aromatic or heteroaromatic derivatives |
| 09/27/2001 | US20010025046 A stabilized self-emulsifying system, comprising a o-(chloroacetylcarbamoyl)fumigillol drug, a carrier which is an oily constituent, a surfactant and a stabilizer; angiogenesis inhibitor |
| 09/27/2001 | US20010025044 A bicyclic nitrogen containing heteroaromatic compound useful for inhibiting protein kinase p38 which involved in cell proliferation, cell death and response to extracellular stimuli |
| 09/27/2001 | US20010025036 Modifying the structure of a 1alpha-hydroxylated vitamin D compound to increase its in vivo activity by altering the conformational equilibrium of the A-ring to favor a chair conformation that presents 1alphahydroxy in axial orientation |
| 09/27/2001 | US20010025035 Water soluble prodrugs of hindered alcohols |
| 09/27/2001 | US20010025032 Administering mixture of nucleosides; anticancer agent |
| 09/27/2001 | US20010025030 cDNA for human methylenetetrahydrofolate reductase and uses thereof |
| 09/27/2001 | US20010025029 Novel stromelysin inhibitors |
| 09/27/2001 | US20010024813 Human dendriac and brainiac-3 |
| 09/27/2001 | US20010024786 Purified polypeptide of given sequence; useful in diagnosis, prevention, and treatment of cancer, inflammation, and disorders of fatty acid metabolism |
| 09/27/2001 | US20010024664 Alzheimer's diseases; central nervous system disorders; antiinflammatory agent; solvent extraction from plants |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024650 Artery - and vein-specific proteins and uses therefor |
| 09/27/2001 | US20010024648 Four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effeftive immunosuppressants for the treatment of autoimmune diseases and prevent organ trasplant rejection |
| 09/27/2001 | US20010024636 Thermally reversible stimulus- sensitive gel or gelling copolymer radioisotope carrier that is a linear random copolymer of an (meth)acrylamide derivative and a hydrophil comonomer |
| 09/27/2001 | US20010023877 Inverted aerosol dispenser |
| 09/27/2001 | DE10012151A1 Aerosol inhalant containing vitamin A compound in liposomes based on phosphatidylcholine, useful for treatment of tracheo-bronchial illnesses, especially chronic obstructive pulmonary disease |
| 09/27/2001 | DE10012120A1 New ligand, comprising therapeutic or diagnostic agent bonded non-covalently with substance having high affinity to transport molecule |
| 09/27/2001 | DE10011530A1 New antisense oligonucleotides that inhibit polo-like kinase, useful for treating tumors that overexpress this kinase, have strong and selective action |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404275A1 Cosmetic use of hop and ornithine |
| 09/27/2001 | CA2404236A1 Carbocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 09/27/2001 | CA2404216A1 Novel polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | CA2404131A1 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors |
| 09/27/2001 | CA2404088A1 Bi-functional cancer treatment agents |
| 09/27/2001 | CA2404076A1 Heterocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2404002A1 Inhibitors of histone deacetylase |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403823A1 Thioketals and thioethers for inhibiting the expression of vcam-1 |
| 09/27/2001 | CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403809A1 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | CA2403804A1 Vegf-modulated genes and methods employing them |
| 09/27/2001 | CA2403803A1 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid |
| 09/27/2001 | CA2403795A1 Osteocalcin promoter directed adenovirus replicaton for therapy |
| 09/27/2001 | CA2403778A1 Carbocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2403760A1 Detection of immunological memory, t-cell conjugates for pathology imaging and therapy |
| 09/27/2001 | CA2403684A1 Therapeutic anti-melanoma compounds |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2403461A1 Sponge antitumor compounds |
| 09/27/2001 | CA2402834A1 Brca-1 regulators and methods of use |
| 09/27/2001 | CA2402816A1 Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402643A1 Polyglutamic acid-camptothecin conjugates and methods of preparation |
| 09/27/2001 | CA2402596A1 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 09/27/2001 | CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/27/2001 | CA2401887A1 Nusap, a novel gene encoding a tissue-specific nuclear protein, useful as a diagnostic tool and therapeutic agent |
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2401728A1 Difluorobutyric acid metalloprotease inhibitors |
| 09/27/2001 | CA2401368A1 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors |
| 09/27/2001 | CA2400645A1 Taxane anticancer agents |
| 09/27/2001 | CA2400638A1 7 human ovarian and ovarian cancer associated proteins |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | CA2399991A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | CA2374073A1 Novel polypeptides and nucleic acids encoding same |
| 09/26/2001 | EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy |
| 09/26/2001 | EP1136561A2 Targeting gene therapy |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136500A2 Seroreactive regions from the HPV proteins E1 and E2 |
| 09/26/2001 | EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1135998A1 Use of synthetic triglycerides based on conjugated linoleic acid as antioxydant in foodstuffs |
| 09/26/2001 | EP1135996A1 Use of synthetic triglycerides based on conjugated linoleic acid as colour stabilisor in foodstuffs |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135516A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
| 09/26/2001 | EP1135515A2 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 09/26/2001 | EP1135513A1 Adenovirus-mediated gene therapy |
| 09/26/2001 | EP1135504A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 09/26/2001 | EP1135498A1 Antibody variants with higher binding affinity compared to parent antibodies |
| 09/26/2001 | EP1135495A2 Secreted amd transmembrane polypeptides and nucleic acids encoding the same |
| 09/26/2001 | EP1135494A2 Neuron-associated proteins |
| 09/26/2001 | EP1135491A2 Methods and compositions for inhibiting neoplastic cell growth |
| 09/26/2001 | EP1135486A1 RECOMBINANT SOLUBLE Fc RECEPTORS |
| 09/26/2001 | EP1135485A2 Promotion or inhibition of angiogenesis and cardiovascularization |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135482A1 Cancer cell vaccine |
| 09/26/2001 | EP1135481A1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 09/26/2001 | EP1135477A1 Humanized monoclonal antibodies |
| 09/26/2001 | EP1135470A2 Recombinant methods and materials for producing epothilone and epothilone derivatives |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135467A1 Psca: prostate stem cell antigen and uses thereof |
| 09/26/2001 | EP1135413A2 Proteins that bind angiogenesis-inhibiting proteins, compoisitions and methods of use thereof |
| 09/26/2001 | EP1135401A1 Glyceryl nucleotides, method for the production thereof and their use |
| 09/26/2001 | EP1135390A1 Methotrexate derivatives |
| 09/26/2001 | EP1135379A1 Antitumor dibenzofluorene derivatives |
| 09/26/2001 | EP1135374A1 Benzimidazole compounds that are vitronectin receptor antagonists |
| 09/26/2001 | EP1135373A1 Crystalline form of an octahydro-benzo(f)quinolin-3-one derivative |
| 09/26/2001 | EP1135193A1 Agents provided for treating tumors, based on liposomes, and containing tamoxifen |
| 09/26/2001 | EP1135178A1 Polymeric coatings with controlled delivery active agents |
| 09/26/2001 | EP1135169A1 Pharmaceutical composition comprising an anti-cancer agent and at least a peptide |
| 09/26/2001 | EP1135168A1 Peptides carrying substances across the blood brain barrier |
| 09/26/2001 | EP1135162A2 Ordered molecular presentation of antigens, method of preparation and use |
| 09/26/2001 | EP1135161A1 Chemotherapeutic composition and method |
| 09/26/2001 | EP1135160A2 Boron neutron capture therapy using pre-targeting methods |